Interview: Eisai India Unit’s Pivotal Role As Japan Genericizes
Executive Summary
Eisai India chief Dr. Sanjit Singh Lamba outlines the competitive edge that the Japanese group’s Indian site offers under the deal with Nichi-Iko; the site has also never “depended” on active pharmaceutical ingredients from China. In a wide-ranging interview with Scrip, Lamba also discusses recent quality compliance initiatives in India.
You may also be interested in...
Eisai Seeks To Block Dr Reddy’s Over Belviq Plans In India
Eisai has moved court against Dr Reddy’s for alleged infringement of its patent on Belviq in India. The case is expected to put the spotlight back on prickly IPR issues, including working of patents.
Third Party Manufacturer Lapses – Marketers Will Need To Share Onus In India
Drug marketers who don’t own-manufacture products in India may no longer be able to shrug off responsibility in the event of quality lapses at their third-party manufacturers.
Eisai Primes Push For Biogen MS Range In India
Eisai is straddling a mix of new opportunities for growth in India as it takes charge of sales of Biogen’s multiple sclerosis portfolio in the country and also eyes potential gains from its Japanese parent’s recent deal with Nichi-Iko.